GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (India)
CIN : L26109GA1981PLC000469 GSTIN : 30AAACG7070R1ZE

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website: www.gkb.net

GKB /STK-EXCH
November 12, 2026

Department of Corporate Services
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref : Scrip Code No. : 533212

Sub : Outcome of Board Meeting of GKB Ophthalmics Limited held on November 12, 2026.

The meeting of the Board of Directors of the Company was held on November 12, 2026, which has inter-alia considered and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

1. Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the following:

   a) Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026, together with the Limited Review Report.

   b) Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with Limited Review Report.

   The above Unaudited Financial Results and the Limited Review Reports are available on the Company's website www.gkb.net and on the BSE website www.bseindia.com

2. The Board of Directors considered and decided to Exit/debond Company's Plant at Unit II (a 100% Export Oriented Unit located at D2, 14, 18 & 19, Tivim Industrial Estate, Mapusa – Goa) pursuant to a review of the Company's current business operations, export orders and prevailing market conditions. Although the scheme was previously commercially viable due to high custom duties on imported goods, subsequent duty reductions have significantly diminished these financial benefits. Following the debonding process, the facility at Unit II will transition to operate as a Domestic Tariff Area (DTA) Unit. Furthermore, this transition will not impact the company's ongoing operations or turnover.

GKB Ophthalmics Ltd.
16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (India)
CIN : L26109GA1981PLC000469 GSTIN : 30AAACG7070R1ZE

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website: www.gkb.net

3. The Board of Directors decided to sub-lease its unutilized building at Plot 16-C&D (constructed for Rs. 3.85 crores adjacent to Plot 16-A) at prevailing market rates, as it remained vacant following the COVID- 19 pandemic. Management is initiating the required licenses and clearances from the Industrial Development Corporation prior to leasing. Concurrently, an analysis of current market rates is underway to secure optimal rental returns. As the investment exceeds the statutory threshold under Section 180(1)(a) of the Companies Act, 2013, this proposal will be submitted to the Board to seek shareholder approval in due course.

The Board of Directors' Meeting started at 04:05 P.M. and ended at 4:40 P.M., on the same day.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For GKB Ophthalmics Ltd.,

KRISHNA GOPAL GUPTA
Digitally signed by KRISHNA GOPAL GUPTA
Date: 2026.11.12 16:44:10 +05'30'

K.G. Gupta
Managing Director

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Floor 6, Building No. 1
Cerebrum IT Park, Kalyani Nagar
Pune 411014, INDIA

Independent Auditor's Review Report on Standalone unaudited financial results of GKB Ophthalmics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

AKSHAY KUMAWAT
Digitally signed by AKSHAY KUMAWAT
Date: 2026.11.12 16:54:32 +05'30'

Akshay Kumawat
Partner
Membership No.: 152924
UDIN: 26152924DBFPGM8509

Place: Sawai Madhopur, Rajasthan
Date: November 12, 2026

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469
Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526
Tel No. (0832) 6714444 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2026

(INR In Lakhs)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sep 30, 2026	June 30, 2026	Sep 30, 2025	Sep 30, 2026	Sep 30, 2025	Mar 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income:						
1	Revenue from operations	679.23	639.89	610.64	1,319.12	1,488.13	2,564.41
2	Other income	2.50	47.35	136.68	49.85	143.69	596.81
3	**Total income (1+2)**	**681.73**	**687.24**	**747.32**	**1,368.97**	**1,631.82**	**3,161.22**
4	**Expenses:**	0.53	0.48	0.43	0.51	0.52	0.52
	a) Cost of materials consumed	335.88	328.77	298.26	664.65	811.45	1,269.49
	b) Changes in inventories of finished goods and work-in-progress	20.87	(18.50)	(35.96)	2.37	(44.83)	52.19
	c) Employee benefits expense	199.57	221.77	259.35	421.34	543.06	967.11
	d) Finance costs	28.61	29.86	57.10	58.47	125.59	217.10
	e) Depreciation and amortisation expense	66.10	65.76	67.87	131.86	134.68	268.75
	f) Other expenses	146.61	133.52	151.17	280.13	324.85	572.08
	Total expenses	**797.64**	**761.18**	**797.79**	**1,558.82**	**1,894.80**	**3,346.72**
5	**Profit / (Loss) before exceptional items and tax (3-4)**	**(115.91)**	**(73.94)**	**(50.47)**	**(189.85)**	**(262.98)**	**(185.50)**
	Exceptional items (Refer Note 6)	-	-	-	-	-	178.99
6	**Profit / (Loss) before tax**	**(115.91)**	**(73.94)**	**(50.47)**	**(189.85)**	**(262.98)**	**(364.49)**
7	Tax expenses						
	a) Current Tax	-	-	-	-	-	-
	b) Tax adjustments of earlier years	-	(25.53)	-	(25.53)	-	-
	c) Deferred Tax charge / (credit)	-	-	1.79	-	3.58	(7.70)
	Total Tax expense	**-**	**(25.53)**	**1.79**	**(25.53)**	**3.58**	**(7.70)**
8	**Profit / (Loss) for the periods / year (6-7)**	**(115.91)**	**(48.41)**	**(52.26)**	**(164.32)**	**(266.56)**	**(356.79)**
9	**Other comprehensive income:**						
	Items that will not be reclassified to profit or loss						
	Re-measurement gains / (losses) on defined benefit plans	26.72	(6.88)	(6.88)	19.84	(13.76)	29.61
	Income tax effect	-	-	1.79	-	3.58	(7.70)
	Total Other comprehensive Income / (loss) for the periods / year	**26.72**	**(6.88)**	**(5.09)**	**19.84**	**(10.18)**	**21.91**
10	**Total Comprehensive income / (loss) for the periods / year, net of tax (8-9)**	**(89.19)**	**(55.29)**	**(57.35)**	**(144.48)**	**(276.74)**	**(334.88)**
11	**Paid-up equity share capital (face value of share - Rs. 10 each fully paid up)**	504.06	504.06	504.06	504.06	504.06	504.06
12	**Other Equity**						928.48
13	**Earnings Per Share (face value of Rs. 10 each)**						
	(a) Basic (in INR)	(2.30)	(0.96)	(1.04)	(3.26)	(5.29)	(7.08)
	(b) Diluted (in INR)	(2.30)	(0.96)	(1.04)	(3.26)	(5.29)	(7.08)
	* Not Annualised	*	*	*	*	*	

See accompanying notes

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Notes to the Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2026:

1 Standalone Statement of Assets and Liabilities

(INR in Lakhs)

Particulars	As at Sep 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,137.91	1,249.16
Capital work-in-progress	378.30	378.30
Financial assets		
(i) Investments	28.78	18.55
(ii) Other Financial assets	5.39	6.99
Income tax assets (net)	16.44	29.34
Other non-current assets	364.72	276.70
Total Non-current assets	**1,931.54**	**1,959.04**
Current Assets		
Inventories	526.52	517.53
Financial Assets		
(i) Trade Receivables	572.13	518.25
(ii) Cash and cash equivalent	0.05	0.05
(iii) Bank balances other than Cash and cash equivalent	194.06	222.97
(iv) Other financial assets	118.09	376.42
Other current assets	80.31	65.85
Total current assets	**1,491.16**	**1,701.07**
TOTAL ASSETS	**3,422.70**	**3,660.11**
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	504.06	504.06
Other equity	784.00	928.48
Total Equity	**1,288.06**	**1,432.54**
LIABILITIES		
Non - Current liabilities		
Financial liabilities		
(i) Borrowings	111.75	102.34
Provisions	411.30	407.40
Total Non- Current liabilities	**523.05**	**509.74**
Current liabilities		
Financial liabilities		
(i) Borrowings	807.50	851.32
(ii) Trade Payables		
Total outstanding dues of micro enterprises and small enterprises	68.72	105.04
Total outstanding dues of creditors other than micro enterprises and small enterprises	434.00	399.35
(iil) Other financial liabilities	158.36	210.09
Other current liabilities	25.24	18.75
Provisions	117.77	133.28
Total Current liabilities	**1,611.59**	**1,717.83**
Total Liabilities	**2,134.64**	**2,227.57**
TOTAL EQUITY AND LIABILITIES	**3,422.70**	**3,660.11**

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

2 Standalone Statement of Cash Flows **(INR in Lakhs)**

	Particulars	For the Half Year Ended	
		Sep 30, 2026 (Unaudited)	Sep 30, 2025 (Unaudited)
A	**Cash flow from operating activities**		
	(Loss) before tax	(189.85)	(262.98)
	Adjustments for:		
	Depreciation and amortization expense	131.86	134.68
	Finance costs	58.47	125.59
	Provision for / (Reversal of) Doubtful / Bad Debts (net)	(3.13)	13.15
	Unrealised exchange loss /(gain) (net)	2.37	(6.06)
	Dividend income	-	(0.04)
	Interest income	(33.10)	(2.33)
	Liabilities written back	-	(108.36)
	(Gain)/ loss on sale of property, plant and equipment (net)	-	(21.09)
	Operating Profit/ (Loss) before working capital changes	**(33.38)**	**(127.44)**
	Changes in working capital		
	Decrease/ (Increase) in inventories	(8.99)	(0.14)
	Decrease/ (Increase) in trade receivables	(47.39)	180.47
	Decrease/ (Increase) in financial assets	79.50	-
	Decrease/ (Increase) in Non current assets	(109.38)	(19.26)
	Decrease/ (Increase) in current assets	(14.46)	(27.65)
	(Decrease)/ Increase in trade payables	(7.40)	(8.01)
	(Decrease)/ Increase in financial liabilities	(46.65)	(2.01)
	(Decrease)/ Increase in provisions	8.23	23.67
	(Decrease)/ increase in other current liabilities	6.50	15.83
	Cash generated from / (Used in) operations	**(173.42)**	**35.46**
	Income tax (paid) / refund (net)	38.43	(0.83)
	Net cash flows from / (Used in) operating activities (A)	**(134.99)**	**34.63**
B	**Cash flow from Investing activities**		
	Payment for purchase of property, plant and equipment and intangible assets including movement in capital advance	(4.34)	(71.19)
	Proceeds from sale / disposal of property, plant and equipment	-	22.00
	(Purchase of) / proceeds from sale of current investments (net)	(10.23)	-
	Net proceeds from / (amount deposited into) fixed deposits	30.51	44.92
	Interest received	27.55	2.81
	Dividend received	184.38	125.54
	Net cash flow from / (Used in) investing activities (B)	**227.87**	**124.08**
C	**Cash flow from Financing activities**		
	Proceeds from / (Repayment of) short term borrowings (net)	(24.34)	26.22
	Proceeds from long term borrowings	59.00	-
	Repayment of long term borrowings	(69.07)	(59.25)
	Interest paid	(58.47)	(125.59)
	Net cash flow from / (Used in) financing activities (C)	**(92.88)**	**(158.62)**
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	-	0.09
	Cash and cash equivalents at the beginning of the period	0.05	0.04
	Cash and cash equivalents at the end of the period	**0.05**	**0.13**
	Cash and cash equivalents comprise		
	Balances with banks		
	in current accounts	0.03	0.03
	Cash on hand	0.02	0.10
	Total cash and bank balances at end of the period	**0.05**	**0.13**

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

3 The above standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") prescribed under section 133 of Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), both as amended from time to time.

4 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above standalone financial results of GKB Ophthalmics Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their meetings held on November 12, 2026. These unaudited standalone financial results have been subjected to limited review by the statutory auditors of the Company and they have issued an unmodified review report.

5 In accordance with Ind AS 108, Operating segments,the Company has disclosed the segment information in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results.

6 On November 21, 2025, the Government of India notified the four labour codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as “the Labour Codes”).
Based on the requirements of New Labour Codes and relevant Accounting Standards, the Company has estimated the liability for employee benefits, which has resulted in an incremental expense, on account of recognition of past service cost on account of gratuity and leave encashment liability to employees aggregating to Rs. 178.99 lakhs for the year ended March 31, 2026, which was reported as an exceptional item. The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on the New Labour Codes and would provide appropriate accounting effect on the basis of such developments, in future, as needed.

7 The unaudited standalone financial results for the quarter and half year ended September 30, 2026, are available on the BSE Limited website (URL:www.bseindia.com) and on the Company’s website.

For and on behalf of the Board of Directors
of GKB Ophthalmics Limited

KRISHNA GOPAL GUPTA
Digitally signed by KRISHNA GOPAL GUPTA
Date: 2026.11.12 16:46:03 +05'30'

K. G. Gupta
Managing Director
DIN : 00051863

Place : Mapusa - Goa
Date : November 12, 2026

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Floor 6, Building No. 1
Cerebrum IT Park, Kalyani Nagar
Pune 411014, INDIA

Independent Auditor's Review Report on consolidated unaudited financial results of GKB Ophthalmics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Holding Company'), its subsidiary (including step-down Subsidiaries) (the Holding Company and its Subsidiary including step down Subsidiaries together referred to as the 'Group') and its share of the net loss after tax and total comprehensive loss of its associate for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of person responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No.	Name of the Entity	Relationship with the Holding Company
1	GSV Ophthalmics Private Limited	Subsidiary (till November 21, 2025)
2	GKB Ophthalmics Products [FZE]	Subsidiary
	(including its Subsidiaries and Associate as below) a. Lensco -The Lens Company (Subsidiary) b. Prescription Optical Products LLC (Subsidiary) c. Prime Ophthalmic Products (PTY) Ltd (Subsidiary – till July 02, 2026) d. GKB Vision FZC (Associate)	

Floor 6, Building No. 1
Cerebrum IT Park, Kalyani Nagar
Pune 411014, INDIA

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the interim financial information of two step-down subsidiaries which are not subject to review, whose interim financial information reflect total assets of INR 92.04 lakhs as at September 30, 2026 and total revenue of INR 82.62 lakhs and INR 176.72 lakhs, total net profit/(loss) after tax of INR (1.27) lakhs and INR 13.37 lakhs and total comprehensive income / loss of INR (1.27) lakhs and INR 13.37 lakhs for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, and cash outflows (net) of INR 4.97 lakhs for the period from April 01, 2026 to September 30, 2026, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of INR 5.60 lakhs and INR 13.03 lakhs and total comprehensive loss of INR 5.60 lakhs and INR 13.03 lakhs for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, as considered in the Statement, in respect of an associate, based on their interim financial information which are not subject to review. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these step-down subsidiaries and an associate is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

AKSHAY KUMAWAT

Digitally signed by
AKSHAY KUMAWAT
Date: 2026.11.12 16:55:24
+05'30'

Akshay Kumawat
Partner
Membership No.: 152924
UDIN: 26152924XGUAUT9465

Place: Sawai Madhopur, Rajasthan
Date: November 12, 2026

GKB Ophthalmics Limited

CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526

Tel No. (0832) 6714444 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026

(INR In Lakhs)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sep 30, 2026	June 30, 2026	Sep 30, 2025	Sep 30, 2026	Sep 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income:						
1	Revenue from operations	3,274.58	3,303.97	3,017.22	6,578.55	6,247.73	14,906.35
2	Other income	62.29	72.53	36.87	134.82	57.81	224.48
3	**Total Income (1+2)**	**3,336.87**	**3,376.50**	**3,054.09**	**6,713.37**	**6,305.54**	**15,130.83**
4	**Expenses:**						
	a) Cost of materials consumed	550.81	491.59	543.36	1,042.40	1,206.02	2,030.24
	b) Purchases of stock in trade	1,567.57	2,059.64	1,644.77	3,627.21	3,506.88	8,973.21
	c) Changes in inventories of finished goods, stock in trade and work-in progress	148.01	(284.72)	(332.77)	(136.71)	(668.12)	(463.76)
	d) Employee benefits expense	345.65	360.50	437.32	706.15	917.17	1,610.69
	e) Finance costs	42.70	51.25	65.60	93.95	142.23	267.45
	f) Depreciation and amortisation expense	80.64	80.12	81.77	160.76	161.68	323.70
	g) Other expenses	404.93	406.29	419.85	811.22	900.47	1,894.06
	Total expenses	**3,140.31**	**3,164.67**	**2,859.90**	**6,304.98**	**6,166.33**	**14,635.59**
5	**Profit / (Loss) before share of profit / (loss) of an associate, exceptional item and tax (3-4)**	**196.56**	**211.83**	**194.19**	**408.39**	**139.21**	**495.24**
6	**Share in profit / (loss) of an associate**	(5.60)	(7.43)	(2.88)	(13.03)	(4.24)	(5.88)
7	**Profit / (Loss) before exceptional items and tax (5+6)**	**190.96**	**204.40**	**191.31**	**395.36**	**134.97**	**489.36**
	Exceptional items (Refer Note 7)	-	-	-			178.99
8	**Profit / (Loss) before tax**	**190.96**	**204.40**	**191.31**	**395.36**	**134.97**	**310.37**
9	**Tax expenses**						
	a) Current Tax	69.29	43.49	5.40	112.78	11.34	15.36
	b) Tax adjustments of earlier years	-	(25.53)	-	(25.53)	-	-
	c) Deferred Tax charge / (credit)	-	-	1.79	-	3.58	(7.70)
	Total Tax Expense	**69.29**	**17.96**	**7.19**	**87.25**	**14.92**	**7.66**
10	**Profit / (loss) for the period / year (8-9)**	**121.67**	**186.44**	**184.12**	**308.11**	**120.05**	**302.71**
11	**Other comprehensive Income :-**						
	Items that will not be reclassified subsequently to statement of profit or loss						
	Re-measurement gains / (losses) on defined benefit plans	26.72	(6.88)	(6.88)	19.84	(13.76)	29.61
	Income tax effect	-	-	1.79	-	3.58	(7.70)
	Total	**26.72**	**(6.88)**	**(5.09)**	**19.84**	**(10.18)**	**21.91**
	Items that will be reclassified to statement of profit or loss in subsequent periods / year						
	Exchange differences on translation of financial statements of foreign operation	29.02	(72.29)	(125.76)	(43.27)	(151.98)	(427.88)
	Total	29.02	(72.29)	(125.76)	(43.27)	(151.98)	(427.88)
	Total Other comprehensive Income / (loss) for the period / year, net of tax	**55.74**	**(79.17)**	**(130.85)**	**(23.43)**	**(162.16)**	**(405.97)**
12	**Total Comprehensive income / (loss) for the period / year (10+11)**	**177.41**	**107.27**	**53.27**	**284.68**	**(42.11)**	**(103.26)**
13	**Profit /(Loss) for the period / year attributable to**						
	Owners of the parent	66.12	100.69	160.03	166.81	58.21	121.85
	Non-controlling interest	57.34	83.96	24.09	141.30	61.84	180.86
	Total	123.46	184.65	184.12	308.11	120.05	302.71
	Other comprehensive income / (loss) for the period / year attributable to						
	Owners of the parent	59.86	(77.18)	(106.32)	(17.32)	(129.40)	(325.51)
	Non-controlling interest	(5.91)	(0.20)	(24.53)	(6.11)	(32.76)	(80.46)
	Total	53.95	(77.38)	(130.85)	(23.43)	(162.16)	(405.97)
	Total Comprehensive income / (loss) for the period / year attributable to						
	Owners of the parent	125.98	23.51	53.71	149.49	(71.19)	(203.66)
	Non-controlling interest	51.43	83.76	(0.44)	135.19	29.08	100.40
	Total	177.41	107.27	53.27	284.68	(42.11)	(103.26)
14	**Paid-up equity share capital (face value of share - Rs. 10 each)**	504.06	504.06	504.06	504.06	504.06	504.06
15	**Other Equity**						4,779.25
16	**Earnings Per Share (face value of Rs. 10 each)**						
	(a) Basic (in INR)	1.31	2.00	3.17	3.31	1.15	2.42
	(b) Diluted (in INR)	1.31	2.00	3.17	3.31	1.15	2.42
	* Not Annualised	*	*	*	*	*	

See accompanying notes

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Notes to the Consolidated Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026:

1 Statement of Consolidated Assets and Liabilities

(INR in Lakhs)

Particulars	As at Sep 30, 2026 (Unaudited)	As at Mar 31, 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,352.09	1,482.30
Capital work-in-progress	378.30	378.30
Other intangible assets	17.57	18.64
Financial assets		
(i) Investments	192.53	195.33
(ii) Other Financial assets	5.39	6.99
Income Tax Assets (Net)	16.44	29.34
Other non-current assets	433.50	309.69
Total Non-current assets	**2,395.82**	**2,420.59**
Current Assets		
Inventories	5,611.16	5,463.08
Financial Assets		
(i) Trade Receivables	4,301.51	4,486.69
(ii) Cash and cash equivalents	958.92	266.69
(iii) Bank balances other than cash and cash equivalents	194.06	222.97
(iv) Other financial assets	35.78	110.16
Other current assets	268.47	246.46
Total current assets	**11,369.90**	**10,796.05**
TOTAL ASSETS	**13,765.72**	**13,216.64**
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	504.06	504.06
Other equity	5,002.82	4,779.25
Non - Controlling Interest	340.67	205.48
Total Equity	**5,847.55**	**5,488.79**
LIABILITIES		
Non - Current liabilities		
Financial liabilities		
(i) Borrowings	111.75	157.49
Provisions	458.10	451.60
Total Non- Current liabilities	**569.85**	**609.09**
Current liabilities		
Financial liabilities		
(i) Borrowings	953.65	1,008.02
(ii) Trade Payables		
Total outstanding dues of micro enterprises and small enterprises	68.72	105.04
Total outstanding dues of creditors other than micro enterprises and smal lenterprises	5,410.39	5,524.03
(iil) Other financial liabilities	199.43	314.24
Other current liabilities	484.17	32.58
Provisions	119.40	134.85
Current tax liabilities (net)	112.56	-
Total Current liabilities	**7,348.32**	**7,118.76**
TOTAL EQUITY AND LIABILITIES	**13,765.72**	**13,216.64**

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

2 Statement of Consolidated Cash Flows **(INR in Lakhs)**

	Particulars	For the Half Year Ended	
		Sep 30, 2026 (Unaudited)	Sep 30, 2025 (Unaudited)
A	**Cash flow from operating activities**		
	Profit / (Loss) before tax	395.36	134.97
	Adjustments for:		
	Depreciation and amortization expense	160.76	161.68
	Finance cost	93.95	142.23
	Provision for / (Reversal of) Doubtful / Bad Debts (net)	-	43.00
	Liabilities written back	(35.13)	(0.36)
	Unrealised exchange loss /(gain) (net)	2.37	6.07
	(Gain)/ loss on sale of property, plant and equipment (net)	-	(21.09)
	Share of Profit / (loss) in Associate	13.03	4.24
	Dividend income	-	(0.04)
	Interest income	(33.10)	(27.39)
	Operating Profit / (Loss) before working capital changes	**597.24**	**443.31**
	Changes in working capital		
	Decrease/ (Increase) in inventories	(148.08)	(623.43)
	Decrease/ (Increase) in trade receivables	197.40	(467.01)
	Decrease/ (Increase) in financial assets	79.93	5.32
	Decrease/ (Increase) in Non current assets	(121.56)	(16.03)
	Decrease/ (Increase) in current assets	(22.01)	(637.81)
	(Decrease)/ Increase in trade payables	(100.23)	979.60
	(Decrease)/ Increase in financial liabilities	(109.73)	38.34
	(Decrease)/ increase in other current liabilities	451.59	368.83
	(Decrease)/ Increase in provisions	10.89	26.94
	Cash generated from / (Used in) operations	**835.44**	**118.07**
	Income tax (paid) / refund (net)	38.21	(14.81)
	Net cash flows from / (Used in) operating activities (A)	**873.65**	**103.26**
B	**Cash flow from Investing activities**		
	Payment for purchase of property, plant and equipment and intangible assets including movement in capital advance	(35.19)	(87.54)
	Proceeds from sale / disposal of property, plant and equipment	-	22.00
	Proceeds from redemption / (Purchase) of current investments (Net)	(10.23)	-
	Net proceeds from / (amount deposited into) fixed deposits	30.51	3.17
	Interest received	27.55	47.08
	Dividend received	-	0.04
	Net cash flow from / (Used in) investing activities (B)	**12.64**	**(15.25)**
C	**Cash flow from Financing activities**		
	Proceeds from / (Repayment of) short term borrowings (net)	(24.34)	26.38
	Repayment of long term borrowings	(134.77)	(41.80)
	Proceeds from long term borrowings	59.00	31.05
	Interest paid	(93.95)	(145.28)
	Net cash flow from / (Used in) financing activities (C)	**(194.06)**	**(129.65)**
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	692.23	(41.64)
	Cash and cash equivalents at the beginning of the period	266.69	302.12
	Cash and cash equivalents at the end of the period	**958.92**	**260.48**
	Cash and cash equivalents comprise		
	Balances with banks		
	in current accounts	956.68	254.39
	Cash on hand	2.24	6.09
	Total cash and bank balances at end of the period	**958.92**	**260.48**

Notes:

3 The unaudited consolidated financial results include results of:

Name of the Company	**Relationship**
1. GKB Ophthalmics Limited	Holding Company
2. GSV Ophthalmics Private Limited	Subsidiary (till November 21, 2025)
3. GKB Ophthalmics Products [FZE]	Subsidiary
(including its Subsidiaries and Associate)	
a. Lensco – The Lens Company (Subsidiary)	
b. Prescription Optical Products LLC (Subsidiary)	
c. Prime Ophthalmic Products (PTY) Ltd (Subsidiary)	(Till July 02, 2026)
d. GKB Vision FZC (Associate)	

4 The above consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") prescribed under section 133 of Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), both as amended from time to time.

5 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above consolidated financial results of GKB Ophthalmics Limited ("the Holding Company" or "the Company") and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") and its share of profits/ losses in the associate, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their meetings held on November 12, 2026. These unaudited consolidated financial results have been subjected to limited review by the statutory auditors of the Company and they have issued an unmodified review report.

6 The Group's operations predominantly relates to manufacturing and trading in unfinished ophthalmics lenses made up of plastic. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence no separate segment information has been furnished herewith.

7 On November 21, 2025, the Government of India notified the four labour codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as "the Labour Codes").
Based on the requirements of New Labour Codes and relevant Accounting Standards, the Holding Company has estimated the liability for employee benefits, which had resulted in an incremental expense, on account of recognition of past service cost on account of gratuity and leave encashment liability to employees aggregating to Rs. 178.99 lakhs for the year ended March 31, 2026, which was reported as an exceptional item. The Holding Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on the New Labour Codes and would provide appropriate accounting effect on the basis of such developments, in future, as needed.

8 GKB Ophthalmics Products FZE completed the closure formalities of its subsidiary, Prime Ophthalmics Products PTY Limited (step-down subsidiary of the Holding Company) on July 02, 2026. The closure was undertaken pursuant to the challenges encountered in generating sufficient revenue and business opportunities and to avoid incurring further financial losses and the necessary statutory and regulatory formalities in this regard have been completed. Consequent to the closure of the step-down subsidiary and cessation of its operations, the investment held by the Group in the said subsidiary amounting to Rs. 43.50 lakhs had been written off during the quarter ended June 30, 2026.

Further, Prime Ophthalmics Products PTY Limited was not a material subsidiary of the Group and the closure of the same will not materially affect the Group's overall revenue, business and profitability.

9 The unaudited consolidated financial results for the quarter and half year ended September 30, 2026, are available on the BSE Limited website (URL:www.bseindia.com) and on the Company's website.

For and on behalf of the Board of Directors
of GKB Ophthalmics Limited

KRISHNA GOPAL GUPTA
Digitally signed by KRISHNA GOPAL GUPTA
Date: 2026.11.12 16:49:10 +05'30'

K. G. Gupta
Managing Director
DIN : 00051863

Place : Mapusa - Goa
Date : November 12, 2026